QoL · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Haemoglobin (g/dL) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion may leads to higher objective outcome measure: haemoglobin (g/L) compared with conventional medicines (low certainty).
1 finding from 1 review
Objective outcome measure: platelets (× 109/L) · Patients with cancer receiving chemotherapy and/or radiotherapy
1 finding from 1 review
The incidence and severity of toxicities: leukopenia (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment showed no clear difference in the incidence and severity of toxicities: leukopenia (WHO grade 3 to… compared with conventional medicine alone (low certainty).
1 finding from 1 review
QoL · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment may leads to higher qoL (EORTC QLQ‐c30) compared with conventional medicine alone (low certainty).
1 finding from 1 review
Patient‐reported symptom: nausea/vomiting (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment may leads to lower patient‐reported symptom: nausea/vomiting (WHO grade 3 to 4) compared with conventional medicine alone (low certainty).
1 finding from 1 review
Diarrhoea · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment showed no clear difference in patient‐reported symptom: diarrhoea compared with conventional medicine alone (low certainty).
1 finding from 1 review
Objective outcome measure: WBC count (× 109/L) · Patients with cancer receiving chemotherapy and/or radiotherapy
1 finding from 1 review
Haemoglobin (g/dL) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment may leads to higher objective outcome measure: haemoglobin (g/L) compared with conventional medicine alone (low certainty).
1 finding from 1 review
Objective outcome measure: platelets (× 109/L) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment showed no clear difference in objective outcome measure: platelet (× 109/L) compared with conventional medicine alone (low certainty).
1 finding from 1 review
Nausea and vomiting · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diarrhoea · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Objective outcome measure: WBC count (× 109/L) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion may leads to higher objective outcome measure: WBC count (× 109/L) compared with no treatment (low certainty).
1 finding from 1 review
Haemoglobin (g/dL) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion may leads to higher objective outcome measure: haemoglobin (g/L) compared with no treatment (low certainty).
1 finding from 1 review
Objective outcome measure: platelets (× 109/L) · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion may leads to higher qoL (EORTC QLQ‐C30) compared with sham treatment (low certainty).
1 finding from 1 review
Time to death from any cause (here: overall mortality at 12‐month
Pembrolizumab probably leads to lower time to death from any cause (here: overall mortality at 12‐month compared with chemotherapy (moderate certainty).
1 finding from 1 review
Quality of life (Change from baseline to week 15)
Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).
1 finding from 1 review
Brain tumour response rates: complete response (CR) and partial response (PR) combinedNo. of participants: 847(6 RCTs)
Pembrolizumab probably leads to higher response rate (partial and complete response) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality
Pembrolizumab showed no clear difference in treatment‐related mortality compared with chemotherapy (low certainty).
1 finding from 1 review